Expression and effects of JMJD2A histone demethylase in endometrial carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 7, 2014, Pages 3051-3056

  Wang, Hong Li ^a,b   Liu, Mei Mei ^a   Ma, Xin ^a   Fang, Lei ^a   Zhang, Zong Feng ^a   Song, Tie Fang ^a   Gao, Jia Yin ^a   Kuang, Ye ^a   Jiang, Jing ^a   Li, Lin ^a   Wang, Yang Yang ^a   Li, Pei Ling ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Endometrial carcinoma; JMJD2A; Tumor invasion; Tumor migration

Indexed keywords

HISTONE; HISTONE DEMETHYLASE; KDM4A PROTEIN, HUMAN; SMALL INTERFERING RNA;

BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84900867298     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.7.3051     Document Type: Article

References (29)

1. Amant F, Moerman P, Neven P, et al (2005). Endometrial cancer. Lancet, 366, 491-505.
2. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, et al (2004). Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol, 180, 497-504.
3. Arafa M, Somja J, Dehan P, Kridelka F, Goffin F, et al (2010). Current concepts in the pathology and epigenetics of endometrial carcinoma. Pathology, 42, 613-7.
4. Berger CE, Qian Y, Liu G, Chen H, Chen X (2012). p53, a target of estrogen receptor (ER)a, modulates DNA damageinduced growth suppression in ER-positivebreast cancer cells. J Biol Chem, 287, 30117-27.
5. Berry WL, Shin S, Lightfoot SA, Janknecht R (2012). Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol, 41, 1701-6.
6. Berstein LM, Tchernobrovkina AE, Gamajunova VB, et al(2003). Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol, 129, 245-9.
7. Chao A, Wang TH, Lee YS, et al (2006). Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer, 119, 91-8.
8. Cloos PA, Christensen J, Agger K, et al (2006). The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature, 442, 307-11.
9. Dickson RB, Lippman ME (1995). Growth factors in breast cancer. Endocr Rev, 16, 559-89.
10. Di Cristofano A, Ellenson LH (2007). Endometrial carcinoma. Ann Rev Pathol, 2, 57-85.
11. Hecht JL, Mutter GL (2006). Molecular and pathologic aspects ofendometrial carcinogenesis. J Clin Oncol, 24, 4783-91.
12. Li BX, Zhang MC, Luo CL, et al (2011). Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res, 30, 90.
13. Katoh M, Katoh M (2004). Identification and characterization of JMJD2 family genes in silico. Int J Oncol, 24, 1623-8
14. Kauffman EC, Robinson BD, Downes MJ, et al (2011). Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog, 50, 931-44.
15. Kim TD, Shin S, Berry WL, et al (2012). The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem, 113, 1368-76.
16. Qin C, Nguyen T, Stewart J, et al (2002). Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of anuclearfactorB/CCAAT- bindingtranscriptionfactor-1complex. Mol Endocrinol, 16, 1793-809.
17. Ryan AJ, Susil B, Jobling TW, Oehler MK (2005). Endometrial cancer. Cell and Tissue Research, 322, 53-61.
18. Salvesen HB, Haldorsen IS, Trovik J (2012). Markers for individualised therapy in endometrial carcinoma. Lancet Oncol, 13, 353-61.
19. Shah YM, Basrur V, Rowan BG (2004). Selective estrogen receptor modulator regulated proteins in endometrial cancer cells. Mol Cell Endocrinol, 219, 127-39.
20. Shin S, Janknecht R (2007). Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun, 359, 742-6.
21. Shirley SH, Rundhaug JE, Tian J, et al (2009). Transcriptional regulation of estrogen receptor by p53 in human breast cancer cells. Cancer Res, 69, 3405-14.
22. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics. CA Cancer J Clin, 63, 11-30.
23. Sirbasku DA, Moreno-Cuevas JE (2000). Estrogen mitogenic action. ii. negative regulation of the steroid hormoneresponsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications. In Vitro Cell Dev Biol Anim, 36, 428-46.
24. Soto AM, Sonnenschein C (1987). Cell proliferation of estrogensensitive cells: the case for negative control. Endocr Rev, 8, 44-52.
25. Thanapprapasr D, Thanapprapasr K (2013). Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev, 14, 3419-23.
26. Thomas DB (1984). Do hormones cause breast cancer?. Cancer, 53, 595-604.
27. Tsukada Y, Fang J, Erdjument-Bromage H, et al (2006). Histone demethylation by a family of JmjC domain-containing proteins. Nature, 439, 811-6.
28. Vousden KH, and Prives C (2009). Blinded by the light: the growing complexity of p53. Cell, 137, 413-31.
29. Wang XW, Chen YL, Luo YL, Liu QY (2011). No association between the CYP1B1 C4326G polymorphism and endometrial cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 12, 2343-8.